🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just wrapped at #ASCO24: City of Hope's Dr. Al Malki shared promising interim data from our ACCESS trial. “We want more patients to survive and thrive—results from ACCESS to-date have shown positive, significant transplant outcomes and good quality of life for patients.”

CONGRESS #ASCO24 | Monzr M. AlMalki, MD, City of Hope presented findings from the phase II ACCESS study assessing PTCy-based GVHD prophylaxis following MMUD transplantation. GRFS at 1 year was estimated at 47%, with 1 year OS of 79%. #GvHD #GvHDsm

New approach ‘redefining what is a suitable donor’ ASCO NMDP City of Hope for stem cell transplant healio.com/news/hematolog…

A DOCTOR ISN’T BORN, A DOCTOR IS MADE. Dr Honey choudhary 🩺 #Meded #medx

At #ASCO24, Monzr M. AlMalki, MD and Richa Thakur, MD sat down to discuss Dr. Al Malki's presentation about addressing barriers to #transplantation #accessibility. Listen along to the #podcast to learn more: oncdata.com/addressing-bar…

Just published in Journal of Clinical Oncology: Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors | NMDP ascopubs.org/doi/10.1200/JC…

Remember when we used to avoid mismatched unrelated donor transplants for fear of worse GVHD and NRM outcomes? Those days are over. Congrats to the study team!! 🎉CIBMTR NMDP Brian Shaffer Mahasweta Gooptu Javier Bolaños Meade, MD Steve Spellman Antonio Jimenez Jimenez Monzr M. AlMalki, MD #PTCyrules

Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplantation (HCT) mdpi.com/si/217724 #mdpicancers via Cancers MDPI

⁦Monzr M. AlMalki, MD⁩ and PTCy in MUD at ⁦Society of Hematologic Oncology (SOHO)⁩ Saudi Arabia ⁦مستشفى الملك فيصل التخصصي ومركز الأبحاث⁩ ⁦City of Hope⁩

Heading to #Tandem25? Don’t miss oral presentations by Dr. Jeff Auletta and City of Hope's Monzr M. AlMalki, MD on new ACCESS trial research tackling non-HLA barriers in cell therapy and improving all patient outcomes. 🔬 👉 go.nmdp.org/4hMkIP6 👉 go.nmdp.org/40KxNSi

Monzr M. Al Malki, MD, of City of Hope discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation. Watch more here: hubs.ly/Q035PJtf0

Interim analysis of a very promising microchimerism NGS based testing modality “Allo-heme” on ACROBAT study in AML/MDS by Monzr M. AlMalki, MD #Tandem25

Novel engineered Treg product TRX-101 + PTCy in mismatched alloHCT. Early phase I results presented by Monzr M. AlMalki, MD from City of Hope. Is this the future of reducing IST burden? #Tandem25

CONGRESS | #Tandem25 | PRESENTATION Monzr M. AlMalki, MD, City of Hope, presents preliminary results from the phase I ALLOHA trial (NCT05473910) evaluating TSC-100 and TSC-101 TCR-T cells as maintenance treatment post-HCT to prevent relapse in patients with AML, ALL, or MDS undergoing

CONGRESS | #Tandem25 Monzr M. AlMalki, MD, City of Hope presented results from the phase I Alloha trial of TSC-100 & TSC-101 in #AML, #ALL and #MDS post allo-HCT. Infusions were well tolerated with no DLTs. 8% of TSC treated pts relapsed vs 33% in the control arm.

CONGRESS | #Tandem25 Monzr M. AlMalki, MD City of Hope presented results from the ACCESS study which assessed PTCy for #GvHD prophylaxis after MMUD PBSC. 1-year OS was 84%, 56% of pts experienced Grade 2-5 infection in the first 100 days post-transplant. gvhdhub.com/medical-inform…

Tune in to hear Monzr M. AlMalki, MD of City of Hope and Jeff Auletta of NMDP discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies. Watch here: hubs.li/Q0370q550

AlloHeme Enhances Early Relapse Detection in AML and MDS Post-Transplant targetedonc.com/view/alloheme-… via Targeted Oncology City of Hope

Celebrating record-high with 20,000 transplant City of Hope cityofhope.org/twenty-thousan…